UCB licensed ATG‑201, a CD19xCD3 T‑cell engager developed by Shanghai‑based Antengene, paying $80 million up front with up to $1.1 billion in milestones and tiered royalties. Antengene will complete first‑in‑human Phase I studies before transferring the program to UCB for global development and commercialization. UCB called the deal its first entry into T‑cell engagers, a modality gaining attention for oncology and autoimmune indications. The agreement expands UCB’s immunology capabilities and positions ATG‑201 amid a crowded TCE field where differentiation and safety profiles will determine commercial prospects.